# Natalizumab High Titer Immunogenicity and Safety

> **NCT00516893** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 113 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BG00002-E (natalizumab high titer)

## Key facts

- **NCT ID:** NCT00516893
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-10
- **Final completion:** 2007-12
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2014-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516893, "Natalizumab High Titer Immunogenicity and Safety". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00516893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*